Purpose
to compare effect Ranibizumab and Aflibercept, for the treatment of macular edema secondary to nonischemic central retinal vein occlusion CRVO in young adults.
Methods
Forty eyes of 40 young adult patients with macular edema due to CRVO were enrolled in this prospective
double-armed clinical trial. The patients were randomized into 2 groups of 20 patients each. First group
received intravitreal injection of Ranibizumab while second group received Aflibercept. All patients were
subjected to measurement of Best corrected visual acuity BCVA, fluorescein angiography (FA) to detect
retinal ischemia and Spectral domain OCT (SD-OCT) to measure macular edema at baseline and during
12-month follow up period. Intravitreal injections were three injections with a 1-month interval between
injections.
Results
BCVA in group 1 had significant steady increase over time from baseline to 1 year [55.9 ± 10.3], p = 0.017).
Group 2 had also significant steady increase over time from baseline to 1 year [60.8 ± 8.4], p = 0.035) with
no significant difference between the 2 groups (p > 0.05). Regarding central subfield thickness CST, in the
first group, statistically significant decrease in the CST over time from baseline to 1 year [295.1 ± 56 Um],
p < 0.001). similar results in the second group from the baseline to 1 year [328.2 ± 72 Um] with no
statistically significant difference (p > 0.05).
Conclusion
Ranibizumab and aflibercept showed a comparable promising outcome in the management of macular
edema secondary to nonischemic CRVO in patients aged < 50 years |
